Valuation: Sensorion

Market Cap 150M 174M 140M 128M 241M 16.66B 245M 1.65B 645M 8.36B 655M 640M 27.63B P/E 2026 *
-38x
P/E 2027 * -6.33x
Enterprise Value 17.53M 20.43M 16.37M 15.01M 28.24M 1.95B 28.7M 193M 75.62M 979M 76.72M 75.05M 3.24B EV / Sales 2026 *
0.8x
EV / Sales 2027 * 23.4x
Free-Float
70.51%
Yield 2026 *
-
Yield 2027 * -
1 day+1.93%
1 week+0.17%
Current month+2.29%
1 month+11.73%
3 months-25.32%
6 months-5.07%
Current year-13.80%
1 week 0.28
Extreme 0.28
0.3
1 month 0.25
Extreme 0.2475
0.31
Current year 0.22
Extreme 0.222
0.81
1 year 0.22
Extreme 0.222
0.81
3 years 0.15
Extreme 0.1544
1.04
5 years 0.15
Extreme 0.1544
2.29
10 years 0.15
Extreme 0.1544
7.74
Manager TitleAgeSince
Chief Executive Officer 59 01/06/2026
Director of Finance/CFO - 26/06/2024
Chief Tech/Sci/R&D Officer - 11/12/2023
Director TitleAgeSince
Director/Board Member - 09/03/2015
Director/Board Member 43 -
Chairman 61 30/03/2023
Date Insider Type Main position Quantity % Market Cap.
6/2/26
Redmile Biopharma Investments III LP
BuyCompany 18,928,571 6.2956%
31/1/26
Sofinnova Partners SAS
BuyCompany 10,714,285 3.5636%
18/4/24
Redmile Biopharma Investments III LP
BuyCompany 2,781,914 1.0091%
Change 5-day change 1-year change 3-year change Capi.($)
+1.93%+0.17%-21.27%-30.00% 170M
+2.37%+0.66%+4.21%+22.74% 48.63B
-0.62%+4.58%+487.47%+618.65% 46.3B
+2.09%+4.96%+20.59%+92.16% 41.97B
+3.85%+3.13%+29.60%+16.29% 39.51B
-0.72%-7.79%+17.87%+47.98% 31.75B
+3.04%+1.89%+31.62%+147.28% 16.48B
+4.33%+1.63% - - 16.34B
+1.44%+1.09%+4.93%+31.00% 14B
+3.87%+1.98%+82.99%+44.34% 13.33B
Average +1.99%-0.71%+73.11%+110.05% 26.85B
Weighted average by Cap. +1.77%-0.05%+107.35%+155.59%

Financials

2026 *2027 *
Net sales 21.86M 25.48M 20.41M 18.73M 35.21M 2.44B 35.79M 241M 94.31M 1.22B 95.68M 93.6M 4.04B 6.4M 7.46M 5.97M 5.48M 10.3M 713M 10.47M 70.46M 27.59M 357M 27.99M 27.38M 1.18B
Net income -237K -276K -221K -203K -381K -26.37M -388K -2.61M -1.02M -13.23M -1.04M -1.01M -43.73M -36.12M -42.11M -33.73M -30.94M -58.19M -4.02B -59.15M -398M -156M -2.02B -158M -155M -6.67B
Net Debt -132M -154M -123M -113M -213M -14.71B -216M -1.45B -570M -7.38B -578M -565M -24.39B -
Logo Sensorion
Sensorion is a clinical-stage biotech company, that specializes in the development of novel therapies to restore, treat and prevent hearing loss disorders, a significant global unmet medical need. Sensorion has built a R&D technology platform to expand its understanding of the pathophysiology and etiology of inner ear related diseases, enabling it to select the best targets and modalities for drug candidates. Its clinical-stage portfolio includes one Phase 2 product: SENS-401 (Arazasetron) progressing in a proof of concept (PoC) clinical study in cisplatin-induced ototoxicity (CIO) and, with partner Cochlear Ltd, in a study in patients scheduled for cochlear implantation. Sensorion has entered into a strategic collaboration with Institut Pasteur. The company has two gene therapy programmes: SENS-501 for the treatment of hearing loss caused by otoferlin deficiency, and SENS-601 (GJB2-GT) for the treatment of hearing loss associated with mutations in the GJB2 gene.
Employees
63
Date Price Change Volume
19/08/26 0.2905 +1.93% 483,686
18/08/26 €0.2850 -3.39% 644,357
17/08/26 €0.2950 +2.43% 1,742,312
14/08/26 €0.2880 -0.35% 628,357
13/08/26 €0.2890 +1.94% 1,142,885
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
5
Last Close Price
0.2850EUR
Average target price
1.138EUR
Spread / Average Target
+299.12%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. ALSEN Stock